VNDA

Vanda Pharma

• Benzinga·3h ago

  Vanda Pharmaceuticals Announces Initiation Of The Thetis Study, A Clinical Trial Of NEREUS For The Prevention Of Vomiting Induced By GLP-1 Receptor Agonists; Topline Results From Thetis Study Expected By Q4 2026; Phase 2 Study Succeeded And Met Its Primary Endpoint

• TipRanks·3h ago

  Vanda Pharmaceuticals initiates trial of tradipitant in GLP-1-caused vomiting

• Reuters·3h ago

  Vanda starts Thetis trial of NEREUS to curb GLP-1 therapy vomiting

• Reuters·3h ago

  VANDA PHARMACEUTICALS INC: PHASE 2 STUDY SUCCEEDED AND MET ITS PRIMARY ENDPOINT

• TipRanks·6d ago

  Vanda Announces Resignation of Senior Legal Executive

• Reuters·6d ago

  Vanda SVP, General Counsel Timothy Williams resigns effective April 10

• TipRanks·03/30 11:40

  Analysts Offer Insights on Healthcare Companies: Lucid Diagnostics (LUCD), Vanda (VNDA) and Cytokinetics (CYTK)

• Benzinga·03/19 20:39

  Vanda Pharmaceuticals Advocates For Stronger FDA Measures To Accelerate Shift From Animal Testing To Human-Relevant Methods

• Reuters·03/19 20:35

  Vanda Pharmaceuticals urges FDA to revise draft guidance on non-animal testing methods

• Reuters·03/17 16:16

  EMA: ISSUED ITS OPINION ON HETLIOZ MARKETING AUTHORISATION CHANGE AFTER RE-EXAMINATION ON 16 MARCH

• Reuters·03/17 16:16

  EMA: REFUSAL OF CHANGE TO HETLIOZ MARKETING AUTHORISATION TO ADD TREATMENT OF NIGHTTIME SLEEP DISTURBANCE IN ADULTS WITH SMITH-MAGENIS SYNDROME

• TipRanks·03/11 02:27

  Vanda Advances NEREUS Launch With Direct-to-Consumer Strategy

• Benzinga·03/05 12:36

  This Equinix Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

• Dow Jones·03/05 11:34

  Vanda Pharmaceuticals Price Target Announced at $18.00/Share by Truist Securities

• Benzinga·03/05 11:25

  Truist Securities Initiates Coverage On Vanda Pharmaceuticals with Buy Rating, Announces Price Target of $18